- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745186
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
A Randomized, Open Label, Four Way Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety After Intramuscular (IM) Administration of Mayne Glucagon for Injection With Glucagen® (Novo Nordisk) in Healthy Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Glucagon has been shown to be effective in the treatment of hypoglycemia, low blood sugar levels, in patients with diabetes. It primarily functions as a counter-regulatory hormone by opposing the actions of insulin to maintain blood glucose levels. A major problem for diabetic patients with hypoglycemia is the development of defective counter regulatory responses including reduced or absent glucagon responses to hypoglycemia. Mayne Glucagon for Injection has been developed as an alternative to currently marketed products.
Administration of exogenous glucagon i.e., not produced in the body, has been shown to be effective in the treatment of low blood sugar in patients with diabetes. Mayne has developed a product, Glucagon for Injection, which is an alternative to currently marketed products. The only difference is the source of the active ingredient. The formulation, routes of administration, dosage regimen and indications of Mayne Glucagon for Injection are identical to those currently registered for the marketed product.
A total of 28 healthy volunteers will be recruited into this study at one investigational site.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom, EH14 4AP
- Charles River Laboratories
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Male or female aged 18-50 years inclusive
- Body weight between 50 - 100 kg and body mass index (BMI) between 18 and 30 kg/m2 or, if outside the range, considered not clinically significant by the investigator
- Non-smokers or ex-smokers who have not smoked with in the previous 3 months
- Written informed consent given
- Willing and able to comply with the requirements of the protocol and available for the planned duration of the study
- Subject must agree to use an adequate method of contraception during the study and for 12 weeks after the last dose of investigational medicinal product (IMP). Adequate methods of contraception for subject or partner include condoms with spermicide gel, diaphragm with spermicide gel, coil (intrauterine device), surgical sterilisation, subdermal implant, vasectomy, oral contraceptive pill, depot progesterone injections and abstinence. If a volunteer is usually not sexually active but becomes active he/she or their partner must use one of the contraceptive methods listed . Male subjects whose partner is of child bearing potential must ensure that they or their partner use effective contraception for the course of the study and 12 weeks thereafter
Exclusion Criteria:
- History or presence of any clinically significant findings that, in the opinion of the investigator, would preclude inclusion in the study
- History or presence of clinical significant gastrointestinal pathology or symptoms, liver or kidney disease or any other condition that might interfere with the absorption, distribution, metabolism or excretion of the drug.
- Any clinically significant laboratory findings
- Clinically significant abnormalities in 12-lead electrocardiogram (ECG) results
- Positive pregnancy test or lactation
- Participation in any other clinical study using an investigational product or device within the previous 12 weeks
- Positive human immunodeficiency virus (HIV), Hepatitis B or C test
- History of drug or alcohol abuse within the past two years or alcohol consumption greater than 21 units per week for males and greater than 14 units per week for females
- Blood donation of ≥ 500 mL in the previous 12 weeks
- Hypersensitivity to Glucagon and/or any excipients
- Use of prescription medicines or St John's Wort in the previous 2 weeks. The use of over-the-counter medicines within 5 days of dosing except those deemed by the investigator not to interfere with the outcome of the study. Vitamins, minerals and nutritional supplements may be taken at the discretion of the investigator. Hormonal contraceptives will be permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
Glucagen
|
0.2 mg or 1 mg Glucagen single injection
|
EXPERIMENTAL: 2
Mayne Glucagon
|
0.2 mg or 1 mg Mayne Glucagon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Curve from Time 0 to the Last Time Point (AUC0-tlast) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Maximum Glucagon Concentration Observed (Cmax) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Maximum Blood Glucose Concentration Observed (BG Cmax) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20,25,30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20,25,30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Time at which Cmax occurs (Tmax) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Elimination half life (T1/2) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20,25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20,25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Area Under the Curve from Time 0 to the Last Time Point (AUC0-tlast) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Maximum Glucagon Concentration Observed (Cmax) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Time at which Cmax occurs (Tmax) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Elimination half-life (T1/2) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Time at which Blood Glucose Cmax occurs (BG Tmax) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Area under the curve from time 0 to return to baseline (rtb) for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Maximum absolute Blood Glucose excursion (MAE) from baseline for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Area under the glucose excursion versus time curve from 0 to rtb for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
The earliest recorded time of the MAE for 1 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 150, 180 and 240 minutes.
|
Maximum Blood Glucose Concentration Observed (BG Cmax) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Time at which Blood Glucose Cmax occurs (BG Tmax) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Area under the curve from time 0 to return to baseline (rtb) for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Maximum absolute Blood Glucose excursion (MAE) from baseline for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Area under the glucose excursion versus time curve from 0 to rtb for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
The earliest recorded time of the MAE for 0.2 mg Dose Level
Time Frame: Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Pre-dose: 20, 10 and 5 min; Post-dose: 5, 10, 15, 20, 25, 30, 35, 40, 45, 60, 90 and 120 minutes.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stuart Mair, Syneos Health
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLC061
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoglycemia
-
Icahn School of Medicine at Mount SinaiNot yet recruiting
-
University of California, San DiegoDexCom, Inc.Recruiting
-
Vogenx, Inc.Active, not recruitingPostbariatric HypoglycemiaUnited States
-
Joslin Diabetes CenterDexCom, Inc.CompletedHypoglycemia | Hypoglycemia, ReactiveUnited States
-
Nutricia ResearchCompletedPostprandial HypoglycemiaNetherlands
-
PediatrixBanner University Medical CenterTerminatedEffects of a Hypoglycemia Protocol With Glucose Gel on Neonatal Intensive Care Unit (NICU) AdmissionHypoglycemia | Neonatal HypoglycemiaUnited States
-
Tel-Aviv Sourasky Medical CenterUnknown
-
MBX BiosciencesProSciento, Inc.RecruitingPostbariatric HypoglycemiaUnited States
-
University Hospital, Basel, SwitzerlandBoehringer IngelheimRecruitingPostprandial HypoglycemiaSwitzerland
-
University of NebraskaCompletedNeonatal HypoglycemiaUnited States
Clinical Trials on Glucagen
-
Zealand PharmaSynteractHCRCompletedHypoglycemia | Diabetes Mellitus, Type 1United States, Austria, Canada, Germany
-
Steno Diabetes Center CopenhagenRecruitingHypoglycemia | Type 1 DiabetesDenmark
-
Zealand PharmaCompletedHypoglycemia | Diabetes Mellitus, Type 1Canada, United States, Austria, Germany
-
Charite University, Berlin, GermanyUnknownObesity | Diabetes Mellitus, Type 1 | Healthy SubjectsGermany
-
Steno Diabetes Center CopenhagenCompletedHypoglycemia | Type 1 DiabetesDenmark
-
Université Catholique de LouvainFonds National de la Recherche Scientifique; BESPEEDActive, not recruitingType1diabetesBelgium
-
Steno Diabetes Center CopenhagenUniversity of CopenhagenCompletedDiabetes Mellitus | Non-Alcoholic Fatty Liver Disease | Total PancreatectomyDenmark
-
Legacy Health SystemJuvenile Diabetes Research Foundation; Oregon Health and Science UniversityCompletedType 1 Diabetes MellitusUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Germany
-
Inreda Diabetic B.V.WithdrawnDiabetes Mellitus, Type 1Netherlands